TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $960

Benzinga Newsdesk www.benzinga.com Positive 74.1%

Neg 0% Neu 0% Pos 74.1%

TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $880 to $960.